Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents

Journal of Child and Adolescent Psychopharmacology
Carolina Zadrozny Gouvêa da CostaFernando Ramos Asbahr

Abstract

The purpose of this study was to test the efficacy of clomipramine and fluoxetine, controlled by placebo, and compare their action in children and adolescents with anxiety disorders. Thirty subjects (ages 7-17 years), who were diagnosed with generalized anxiety disorder and/or separation anxiety disorder and/or social phobia, were submitted to a 12 week double-blind, randomized, placebo-controlled trial of clomipramine and fluoxetine. The instruments included: the Schedule for Affective Disorders and Schizophrenia, the Multidimensional Anxiety Scale for Children, the Children's Depression Inventory, the Clinical Global Impressions, and the Children's Global Assessment Scale. All groups (clomipramine [n=9], fluoxetine [n=10], placebo [n=11]) showed a significant improvement after 12 weeks of treatment. There were significant differences between the fluoxetine and placebo groups in some ratings of anxiety severity and impairment. No significant differences were observed between clomipramine and placebo groups or between fluoxetine and clomipramine groups. Treatment with placebo showed an unusual high response rate. Clomipramine showed similar efficacy compared with fluoxetine, although it was not superior to placebo.

References

Jan 1, 1992·Journal of the American Academy of Child and Adolescent Psychiatry·R G KleinA Kanner
Nov 1, 1983·Archives of General Psychiatry·D ShafferS Aluwahlia
Feb 1, 1981·The British Journal of Psychiatry : the Journal of Mental Science·T BerneyL Scarth
Apr 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·J S MarchC K Conners
Jan 19, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·P J Ambrosini
Mar 14, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·G A BernsteinC G Last
Oct 9, 2002·The International Journal of Neuropsychopharmacology·Arif KhanWalter A Brown
Mar 22, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Boris BirmaherDavid A Brent
Nov 5, 2003·The American Journal of Psychiatry·Daniel A GellerStephen V Faraone
May 28, 2005·Psychological Medicine·Arif KhanWalter A Browns
Jun 25, 2005·Mental Retardation and Developmental Disabilities Research Reviews·Adrian Sandler
Sep 21, 2005·Child and Adolescent Psychiatric Clinics of North America·E Jane CostelloAdrian Angold
Mar 24, 2006·Journal of Child and Adolescent Psychopharmacology·Laura Seidel, John T Walkup
Dec 16, 2006·Psychotherapy and Psychosomatics·Tina In-Albon, Silvia Schneider
Nov 22, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Deborah C BeidelSanjeev Pathak
Sep 1, 1971·California Medicine·R Gittelman-Klein, D F Klein
Nov 1, 2008·The New England Journal of Medicine·John T WalkupPhilip C Kendall
Jan 13, 2011·Depression and Anxiety·Moira RynnHilary Vidair

❮ Previous
Next ❯

Citations

Mar 31, 2016·Journal of Child and Adolescent Psychopharmacology·Eric T Dobson, Jeffrey R Strawn
Apr 7, 2017·Journal of Child and Adolescent Psychopharmacology·Jeffrey R StrawnMoira A Rynn
Jun 6, 2020·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Jeffrey R StrawnJohn T Walkup
Nov 5, 2019·Journal of the American Academy of Child and Adolescent Psychiatry·Jeffrey A Mills, Jeffrey R Strawn
Sep 25, 2021·Journal of Child and Adolescent Psychopharmacology·Madeeha NasirMichael H Bloch

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
sedation

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.